Prothena Corporation plc (NASDAQ:PRTA) is an Ireland-based late-stage clinical biotechnology company that identifies and ...

Featuring works from Chelsea Odufu, Laurena Finéus, Jarrett Key, and more, the show challenges how we encounter personal ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Sphere Bio, a leading provider of picodroplet-based microfluidics for functional single-cell analysis and isolation, today ...

Other appointments to BIO's board for the 2025 through 2026 term include: Arcutis Bio's Frank Watanabe, named vice-chair; ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

This would mark another shift in Japan’s arms industry, which so far has been largely restricted to producing equipment for ...

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...